You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東曜發佈中報,淨利潤收窄,經營性現金流轉正
格隆匯 09-22 15:14
格隆匯9月22日丨港股大跌之際,東曜藥業-B(1875.HK)今日逆勢上漲,盤中一度漲6%,目前漲2.47%。東曜藥業-B昨日發佈中報顯示,2022年上半年,公司兩款已上市自研產品樸欣汀和替至安的市場渠道持續拓展並取得了亮眼的成績。公司持續推動戰略升級,強化公司在抗體偶聯藥物(antibody-drug conjugates,ADC)領域的競爭優勢,打造國際領先的ADC一站式產業化平台,全力拓展創新藥CDMO業務。截至2022年6月30日止六個月,收入為人民幣1.82億元,同比增長687%。其中主要來自銷貨收入增長至人民幣1.04億元,主要由於樸欣汀獲批上市帶來的業績貢獻,以及CDMO業務收入增長至人民幣2,266萬元,同比增長94%,授權金收入達人民幣4943萬元。2022年上半年,公司的淨虧損為人民幣1572.4萬元;較2021年同期的淨虧損人民幣1.15億元收窄86%。於2022年6月30日,集團的現金及現金等價物為人民幣1.55億元,較2021年底增加207.1萬元。2022年上半年度,集團的經營活動現金淨流入為人民幣2424.1萬元,而2021年同期的經營活動現金淨流出為人民幣9362.4萬元。中報顯示,上半年東曜藥業深化戰略升級,積極推進其自主研發的ADC藥物TAA013(重組人源化抗HER2單克隆抗體(monoclonal antibody,mAb)通過連結子SMCC與微管抑制劑DM1共價連結而成的ADC)的III期臨牀進程。TAA013的III期臨牀試驗入組已結束,目前正在進行受試者的隨訪。針對TAA013的市場合作,公司商務團隊積極尋求海內外合作夥伴,並將遞交EMA諮詢文件。中報還顯示,2022年6月,TAB014(用於治療新生血管濕性老年黃斑部病變,“WAMD”)已順利完成III期臨牀試驗的首例受試者入組,東曜藥業繼續負責臨牀階段產品供應及未來上市商業化生產。TAB014是中國首款進入臨牀階段的用於治療WAMD的重組人源化抗血管內皮細胞生長因子(VEGF)單抗。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account